Munich\/ Hamburg \u2014 hema.to has set itself the task of auto\u00adma\u00adting and fully objec\u00adti\u00adfy\u00ading the clini\u00adcal analy\u00adsis of blood data \u2014 so-called cyto\u00adme\u00adtry \u2014 to enable perso\u00adna\u00adli\u00adzed treat\u00adment for each person\u2019s indi\u00advi\u00addual immune system. Elaia Part\u00adners, Heal Capi\u00adtal and High-Tech Gr\u00fcn\u00adder\u00adfonds (HTGF) support the mission of hema.to with a seed finan\u00adcing round of 3.6 million euros. hema.to will use the funding to scale its AI decis\u00adion support soft\u00adware for blood cancers in Euro\u00adpean labo\u00adra\u00adto\u00adries and provide an initial demons\u00adtra\u00adtion of signi\u00adfi\u00adcant impro\u00adve\u00adment in diagno\u00adstic quality.<\/p>\n
In the diagno\u00adsis of blood cancers and other immune dise\u00ada\u00adses by cyto\u00adme\u00adtry, specia\u00adli\u00adzed analysts and physi\u00adci\u00adans today have to evaluate abstract, high-dimen\u00adsio\u00adnal point clouds based on their expe\u00adri\u00adence and trai\u00adning. This takes a lot of valuable time (between a few minu\u00adtes and hours per sample, about 20 minu\u00adtes on average), which is a problem given the enorm\u00adous and incre\u00adasing shortage of quali\u00adfied labo\u00adra\u00adtory person\u00adnel. Aside from this incre\u00adasing pres\u00adsure on lab staff:inside, this process is noto\u00adriously subjec\u00adtive, with indi\u00advi\u00addual staff analy\u00adses typi\u00adcally diffe\u00adring by 30%.hema.to aims to drama\u00adti\u00adcally improve this process with its state-of-the-art, cloud-based machine lear\u00adning plat\u00adform, helping labs manage their casel\u00adoads, helping lab staff cope with incre\u00adasing demand, provi\u00adding an objec\u00adtive second opinion to any sick person, and provi\u00adding new insights to physi\u00adci\u00adans to tailor treat\u00adment to pati\u00adents\u2019 indi\u00advi\u00addual immune systems.<\/p>\n
On a mission to help labo\u00adra\u00adto\u00adries world\u00adwide with their clini\u00adcal cyto\u00adme\u00adtry workflows<\/strong><\/p>\n \u201cEuro\u00adpe\u2019s largest leuk\u00ademia lab had an urgent need to acce\u00adle\u00adrate its inter\u00adnal analy\u00adsis work\u00adflows and worked with us to deve\u00adlop the worl\u00add\u2019s first AI proto\u00adtype. After the successful demons\u00adtra\u00adtion of AI-assis\u00adted clini\u00adcal cyto\u00adme\u00adtry, we found that all labo\u00adra\u00adto\u00adries shared the same manual work\u00adflows and pain points. We foun\u00added hema.to two years ago to support labo\u00adra\u00adto\u00adries world\u00adwide in their clini\u00adcal cyto\u00adme\u00adtry work\u00adflows,\u201d said Kars\u00adten Mier\u00admans, co-foun\u00adder and CEO of hema.to .<\/strong><\/p>\n Based on a large and growing data\u00adbase of cyto\u00adme\u00adtry data from multi\u00adple sources, hema.to has deve\u00adlo\u00adped algo\u00adrithms that can predict biomar\u00adkers for dise\u00adase directly from raw blood meter data. This pres\u00adents a previously unsol\u00adved chall\u00adenge, as the lack of stan\u00addar\u00addi\u00adzed measu\u00adre\u00adment proto\u00adcols leads to complex data varia\u00adti\u00adons that prevent auto\u00adma\u00adtion. hema.to specia\u00adli\u00adzes in combi\u00adning data from multi\u00adple sources to iden\u00adtify predic\u00adtive biomar\u00adkers for dise\u00adase. The team has alre\u00adady used this tech\u00adno\u00adlogy in clini\u00adcal routine for decis\u00adion support in two labo\u00adra\u00adto\u00adries \u2014 the Insti\u00adtute of Hema\u00adtopa\u00adtho\u00adlogy in Hamburg and the Result Labo\u00adra\u00adtory Dord\u00adrecht \u2014 and now plans to increase the number of user:s and supported dise\u00adase patterns as well as to further improve the quality of the AI models.<\/p>\n hema.to is based in Munich, Germany, and is led by a team of data science experts who have worked closely toge\u00adther for years before hema.to was foun\u00added. Since its incep\u00adtion about two years ago, they have made their product CE-IVD compli\u00adant, conduc\u00adted a clini\u00adcal trial with four centers, and intro\u00addu\u00adced the product into clini\u00adcal prac\u00adtice in two labo\u00adra\u00adto\u00adries. With the second round of funding now raised, the team will be signi\u00adfi\u00adcantly expan\u00added, with a focus on AI and soft\u00adware engi\u00adneers for product deve\u00adlo\u00adp\u00adment, but also immu\u00adno\u00adlogy and cyto\u00adme\u00adtry specia\u00adlists, busi\u00adness deve\u00adlo\u00adp\u00adment and partnerships.<\/p>\n \u201cThe foun\u00adding team, consis\u00adting of three former entre\u00adpre\u00adneurs of the same company with three PhD profiles, convin\u00adced us and is now in the scaling phase. I am deligh\u00adted that hema.to is Elai\u00ada\u2019s first invest\u00adment in Germany,\u201d says Anne-Sophie Carrese, Mana\u00adging Part\u00adner at Elaia Part\u00adners, photo<\/strong>.<\/p>\n About hema.to About Elaia Partners About Heal Capital About High-Tech Gr\u00fcnderfonds <\/p>\n <\/p>\n","protected":false},"excerpt":{"rendered":" Munich\/ Hamburg \u2014 hema.to has set itself the task of auto\u00adma\u00adting and fully objec\u00adti\u00adfy\u00ading the clini\u00adcal analy\u00adsis of blood data \u2014 so-called cyto\u00adme\u00adtry \u2014 to enable perso\u00adna\u00adli\u00adzed treat\u00adment for each person\u2019s indi\u00advi\u00addual immune system. Elaia Part\u00adners, Heal Capi\u00adtal and High-Tech Gr\u00fcn\u00adder\u00adfonds (HTGF) support the mission of hema.to with a seed finan\u00adcing round of 3.6 million [\u2026]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"wp_typography_post_enhancements_disabled":false,"footnotes":""},"categories":[886,1364,1366,1369,1372,1373],"tags":[],"class_list":["post-48956","post","type-post","status-publish","format-standard","hentry","category-general-en","category-featured-en","category-news-en","category-investors","category-consultant","category-venture-capital-en"],"yoast_head":"\n
\n<\/strong>
\nhema.to is an easy-to-use clini\u00adcal decis\u00adion support soft\u00adware for blood cancers based on cyto\u00adme\u00adtry data and using AI. hema.to acce\u00adle\u00adra\u00adtes and impro\u00adves the diagno\u00adstic work\u00adflow and thus helps both diagno\u00adsti\u00adci\u00adans and pati\u00adents. hema.to is CE-IVD and FDA-regis\u00adtered and is alre\u00adady routi\u00adnely used by leading hema\u00adto\u00adlogy labo\u00adra\u00adto\u00adries. Foun\u00added in 2021, hema.to\u2019s mission is to fully objec\u00adtify clini\u00adcal analy\u00adsis of cyto\u00adme\u00adtry data so physi\u00adci\u00adans can tailor treat\u00adment to their pati\u00adents\u2019 indi\u00advi\u00addual immune systems.vwww.hema.to<\/p>\n
\n<\/strong>
\nElaia is a top-tier Euro\u00adpean VC firm with a strong tech\u00adno\u00adlogy DNA. We support tech disrup\u00adt\u00adors with global ambi\u00adti\u00adons from early stage to growth. Over the past 20 years, we have been commit\u00adted to combi\u00adning high perfor\u00admance with values.
\nWe are proud to be an active part\u00adner of over 100 start\u00adups, inclu\u00adding success stories such as Criteo (Nasdaq), Orches\u00adtra Networks (acqui\u00adred by Tibco), Volterra (acqui\u00adred by F5), Mirakl (valued at $3.5 billion in Series E), and Shift Tech\u00adno\u00adlogy (valued at over $1 billion in Series D). www.elaia.com<\/p>\n
\n<\/strong>
\nHeal Capi\u00adtal is a Euro\u00adpean venture capi\u00adtal firm that invests in early and growth-stage tech\u00adno\u00adlogy-based health\u00adcare compa\u00adnies. The 100 million euro fund was initia\u00adted and finan\u00adced by leading private health insu\u00adr\u00aders to actively drive inno\u00adva\u00adtion in health\u00adcare. www.healcapital.com<\/p>\n
\n<\/strong>
\nThe seed inves\u00adtor High-Tech Gr\u00fcn\u00adder\u00adfonds (HTGF) finan\u00adces tech\u00adno\u00adlogy start-ups with growth poten\u00adtial and has supported more than 700 start-ups since 2005. With the launch of the fourth fund, HTGF has around 1.4 billion euros under manage\u00adment. The team of expe\u00adri\u00aden\u00adced invest\u00adment mana\u00adgers and start-up experts supports the young compa\u00adnies with know-how, entre\u00adpre\u00adneu\u00adrial spirit and passion. The focus is on high-tech start-ups in the fields of digi\u00adtal tech, indus\u00adtrial tech, life scien\u00adces, chemis\u00adtry and rela\u00adted busi\u00adness areas. More than \u20ac4.5 billion in capi\u00adtal has been inves\u00adted in the HTGF port\u00adfo\u00adlio by exter\u00adnal inves\u00adtors in more than 2,000 follow-on finan\u00adcing rounds to date. In addi\u00adtion, the fund has alre\u00adady successfully sold shares in more than 160 companies.
\nFund inves\u00adtors in the public-private part\u00adner\u00adship include the German Fede\u00adral Minis\u00adtry for Econo\u00admic Affairs and Climate Protec\u00adtion, KfW Capi\u00adtal, and 45 compa\u00adnies from a wide range of industries.<\/p>\n